Evidence map›Paper›PMID 40029993›Full record

ArticleJournal of medicinal chemistry2025

Nanoenabling MbtI Inhibitors for Next-Generation Tuberculosis Therapy.

Giulia Cazzaniga, Matteo Mori, Anna Griego, Edoardo Scarpa, Giorgia Moschetti, Stefano Muzzioli, Giovanni Stelitano, Laurent R Chiarelli, Mario Cocorullo, Emanuele Casali and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Giulia CazzanigaDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.
Matteo MoriDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.ORCID 0000-0002-7491-1494
Anna GriegoDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.
Edoardo ScarpaDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.
Giorgia MoschettiDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.
Stefano MuzzioliDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.
Giovanni StelitanoDepartment of Biology and Biotechnology "Lazzaro Spallanzani″, University of Pavia, via A. Ferrata 9, 27100 Pavia, Italy.
Laurent R ChiarelliDepartment of Biology and Biotechnology "Lazzaro Spallanzani″, University of Pavia, via A. Ferrata 9, 27100 Pavia, Italy.ORCID 0000-0003-0348-9764
Mario CocorulloDepartment of Biology and Biotechnology "Lazzaro Spallanzani″, University of Pavia, via A. Ferrata 9, 27100 Pavia, Italy.
Emanuele CasaliDepartment of Chemistry, University of Pavia, Viale T. Taramelli 12, 27100 Pavia, Italy.ORCID 0000-0001-7501-5213
Alessio PortaDepartment of Chemistry, University of Pavia, Viale T. Taramelli 12, 27100 Pavia, Italy.ORCID 0000-0002-2564-9696
Giuseppe ZanoniDepartment of Chemistry, University of Pavia, Viale T. Taramelli 12, 27100 Pavia, Italy.
Andrea TresoldiDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.
Elena PiniDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.ORCID 0000-0003-0554-566X
Íris L BatalhaDepartment of Life Sciences, University of Bath, Claverton Down, BA2 7AY Bath, U.K.ORCID 0000-0002-7917-3865
Giuseppe BattagliaMolecular Bionics Group, Institute for Bioengineering of Catalonia (IBEC), C. Baldiri Reixac 10-12, 08028 Barcelona, Spain.
Tiziano TuccinardiDepartment of Pharmacy, University of Pisa, Via Bonanno Pisano 6, 56126 Pisa, Italy.ORCID 0000-0002-6205-4069
Loris RizzelloDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.ORCID 0000-0002-8230-853X
Stefania VillaDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.ORCID 0000-0002-0636-7589
Fiorella MeneghettiDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.ORCID 0000-0002-6511-7360

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The urgent need for safer and innovative antitubercular agents remains a priority for the scientific community. In pursuit of this goal, we designed and evaluated novel 5-phenylfuran-2-carboxylic acid derivatives targeting

Indexed as

Antitubercular AgentsMicrobial Sensitivity TestsMycobacterium tuberculosisAnimalsEnzyme InhibitorsHumansStructure-Activity RelationshipTuberculosisAntitubercular AgentsEnzyme Inhibitors

Identifiers

PMID40029993
PMCPMC11912484

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.